Mutual of America Capital Management LLC Has $13.55 Million Stake in BioLife Solutions, Inc. (NASDAQ:BLFS)

Mutual of America Capital Management LLC grew its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 31.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 521,937 shares of the medical equipment provider’s stock after buying an additional 124,165 shares during the quarter. Mutual of America Capital Management LLC’s holdings in BioLife Solutions were worth $13,549,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares during the last quarter. Geode Capital Management LLC lifted its holdings in BioLife Solutions by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after purchasing an additional 18,473 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in BioLife Solutions by 40.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock worth $487,000 after purchasing an additional 5,638 shares during the last quarter. Barclays PLC lifted its holdings in BioLife Solutions by 20.1% in the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock worth $1,613,000 after purchasing an additional 10,803 shares during the last quarter. Finally, D.A. Davidson & CO. acquired a new stake in BioLife Solutions in the 3rd quarter worth approximately $1,018,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Aby J. Mathew sold 7,604 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $27.33, for a total transaction of $207,817.32. Following the sale, the executive vice president now directly owns 276,315 shares in the company, valued at approximately $7,551,688.95. The trade was a 2.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Troy Wichterman sold 987 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the sale, the chief financial officer now owns 121,779 shares in the company, valued at approximately $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,009 shares of company stock worth $272,594. Company insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on BLFS shares. HC Wainwright reduced their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a report on Monday, November 18th. Craig Hallum lifted their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Northland Securities lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. KeyCorp lifted their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Finally, Benchmark reaffirmed a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $29.43.

BioLife Solutions Stock Performance

BLFS opened at $24.00 on Friday. The stock has a market cap of $1.11 billion, a PE ratio of -22.64 and a beta of 1.91. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 1 year low of $14.50 and a 1 year high of $29.55. The stock’s 50 day simple moving average is $26.81 and its 200-day simple moving average is $25.52.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.